Urea glucokinase activators

Details for Australian Patent Application No. 2008204530 (hide)

Owner Novo Nordisk A/S

Inventors Murray, Anthony; Lau, Jesper; Christiansen, Lise Brown; Vedso, Per

Agent Shelston IP

Pub. Number AU-A-2008204530

PCT Pub. Number WO2008/084044

Priority 07100406.3 11.01.07 EP

Filing date 8 January 2008

Wipo publication date 17 July 2008

International Classifications

C07D 277/48 (2006.01) Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings

A61K 31/54 (2006.01) - having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame

A61P 3/00 (2006.01) Drugs for disorders of the metabolism

Event Publications

23 July 2009 PCT application entered the National Phase

  PCT publication WO2008/084044 Priority application(s): WO2008/084044

11 February 2010 Assignment before Grant

  Novo Nordisk A/S The application has been assigned to TransTech Pharma

25 March 2010 Alteration of Name

  The name of the applicant has been altered to TransTech Pharma, Inc.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008204534-Synthesis

2008204526-Use of MAGE A3-protein D fusion antigen in immunotherapy combined with surgery, chemotherapy or radiotherapy for the treatment of cancer